VERAXA Biotech AG (NASDAQ: VRXA) announced that shareholders have overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company’s outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030, and an increase in the maximum size of the board of directors from five to seven members.
The company stated that the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital markets activities, and continued development of its BiTAC(R) technology platform and oncology pipeline. Management said the vote reflects strong shareholder support for VERAXA’s strategy of advancing antibody-based cancer therapeutics while pursuing long-term value creation.
VERAXA is focused on building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company leverages a suite of transformative technologies and rigorous quality-by-design principles to rapidly advance its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
The approval of these measures is significant as it provides VERAXA with the corporate tools necessary to pursue strategic initiatives without the need for repeated shareholder votes. The capital band, in particular, allows the company to issue shares within a predefined range, streamlining future financing rounds. This could accelerate the development of its oncology pipeline and potentially lead to partnerships or acquisitions that enhance shareholder value. For investors, the high approval rate signals confidence in management's direction and may reduce uncertainty around future capital needs.
For more information, visit the company’s newsroom at http://ibn.fm/VRXA.
